A Phase 1 interventional study of AZD5004 film-coated tablet and [14C]AZD5004 Solution for Infusion in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-28.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study in healthy volunteers aims to answer these questions:
This study will take place at one site in Nottingham, United Kingdom, and plans to enrol 8 healthy men aged 30-65 years, who will be involved in both parts of the study.
In this 2-part study, healthy volunteers will be given three doses of test medicine to find out how the body breaks down and gets rid of the test medicine. Two doses will be 'radiolabelled' - they will contain a small amount of radioactivity (Carbon-14) so that it can be tracked in the body. The amount of radiactivity is less than 6 days of the average radiation exposure received in the UK each year, and slightly less than the radiation dose that would result from a single head x-ray or two leg x-rays.
This study in healthy volunteers aims to answer these questions:
This study will take place at one site in Nottingham, United Kingdom.
It plans to enrol 8 healthy men aged 30-65 years, who will be involved in both parts of the study.
In Part 1, volunteers will receive a single dose of the test medicine by mouth and, on the same day, a very tiny dose of radiolabelled study medicine by injection into a vein. After a minimum of 7 days, in Part 2, volunteers will receive a dose of test medicine containing a very tiny amount of radio label, by mouth. They'll stay in the clinic for up to 6 nights in Part 1 and 8 nights in Part 2 and take up to 7 weeks to finish the study.
We'll collect blood and urine samples to do safety tests. Over a period of at least 15 days, we'll take many blood samples. In Part 2 volunteers will collect all their urine and faeces so that we can measure the amount of test medicine and its breakdown products.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of AZD5004 film-coated tablet and a single dose of \[14C\]AZD5004 Solution for Infusion (Part 1) A single dose of \[14C\]AZD5004 Oral Solution (Part 2)
Drug: AZD5004 film-coated tablet · Drug: [14C]AZD5004 Solution for Infusion · Drug: [14C]AZD5004 Oral Solution
oral, fasted
Also known as: AZD5004
intravenous, fasted
Also known as: [14C]AZD5004
oral, fasted
Also known as: [14C]AZD5004
Absolute bioavailability - Part 1
Absolute bioavailability (F) based on AUC0-inf of oral and IV administration, adjusted for dose
Time frame: Plasma sample collection from pre-dose to 110 hrs post-dose
Amount of AZD5004 excreted (Ae) - Part 2
Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)
Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose
Amount of AZD5004 excreted expressed as a percentage of the dose administered (Fe) - Part 2
Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)
Time frame: Urine and faecal samples collected from pre-dose until 168 hours post dose
Cumulative amount of AZD5004 excreted (CumAe) - Part 2
Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)
Time frame: Urine and faecal samples collected from pre-dose until 168 hours post dose
Cumulative amount of AZD5004 excreted expressed as a percentage of the dose administered (CumFe) - Part 2
Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)
Time frame: Urine and faecal samples collected from pre-dose until 168 hours post dose
Maximum observed concentration (Cmax) for AZD5004 and total radioactivity (TR) - Part 1 and Part 2
Pharmacokinetics (PK) ofAZD5004 and \[14C\]AZD5004 in plasma
Time frame: Plasma sample collection from pre-dose to 110 hours post-dose in Part 1 and from pre-dose to 168 hours post-dose in Part 2
Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD5004 - Part 1 and Part 2
Pharmacokinetics (PK) of AZD5004 and \[14C\]AZD5004 in plasma
Time frame: Plasma sample collection from pre-dose to 110 hours post-dose in Part 1 and from pre-dose to 168 hours post-dose in Part 2
Area under the curve (AUC) of circulating plasma total radioactivity (TR) or accounting for 10% or more of the dose in excreta - Part 2
Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity (TR) or accounting for 10% or more of the dose in excreta
Time frame: Plasma, urine and faecal samples from pre-dose until 168 hours post-dose
Blood:plasma concentration ratios - Part 2
Blood:plasma concentration ratios for total radioactivity (TR)
Time frame: Whole blood and plasma samples collected from pre-dose until 168 hoours post-dose
Number of subjects with treatment-related adverse events - Part 1 and 2
To provide additional safety and tolerability information for AZD5004 by assessing the incidence of AEs
Time frame: Through study duration, approximately 7 weeks
Plan to share: Yes — Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual participant-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in May 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elecoglipron